New data is beginning to shed light on covid-19-related IP filings, but major patent landscape uncertainties pose dangers for research organisations and access to medicine
New data is beginning to shed light on covid-19-related IP filings, but major patent landscape uncertainties pose dangers for research organisations and access to medicine